GlassScriptPhysician profile
Amber D Singer
NPI 1013632835
$613.03
in general payments reported to CMS, 2019-2025
13 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.29 · 2023: $287 · 2024: $112 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.30 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $96.00 | 2023 | Rexulti |
| Novo Nordisk INC | $76.77 | 2023-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.64 | 2025 | Xifaxan |
| Mylan Specialty L.P. | $29.68 | 2022-2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $29.27 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $25.67 | 2025 | |
| Viatris Specialty LLC | $17.36 | 2025 | Yupelri |
| Organon LLC | $16.92 | 2023 | Nexplanon |
| Lilly USA, LLC | $16.89 | 2025 | Mounjaro, Zepbound |
| Lemaitre Vascular, INC. | $16.56 | 2025 | Artegraft Vascular Graft |
| Amgen INC. | $16.13 | 2024 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $15.84 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.